MolecularHealth Signs Internationally-Recognized Oncology Expert to Advisory Board
THE WOODLANDS, TX, UNITED STATES - May 29, 2014 - Today, MolecularHealth announced Waun Ki Hong, M.D., as the newest member of its advisory board. Dr. Hong is one of the nations leading experts on head, neck and lung cancers, recently honored by ASCOs Oncology Luminaries series. This announcement comes on the heels of the commercial launch of TreatmentMAP, MolecularHealths cancer treatment decision support offering.
Waun Ki Hong, M.D., F.A.C.P., D.M.Sc (Hon.), has more than 36 years of experience in translational and clinical cancer research. His contributions to the field of oncology span multiple subsets, including organ preservation, chemoprevention, biomarker-driven personalized therapy and genetic risk models. Currently, Dr. Hong serves as the head of the cancer medicine division at the University of Texas MD Anderson Cancer Center. He is also an American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, professor of thoracic/head and neck medical oncology, and former president of the of the American Association for Cancer Research.
Traditionally, physicians managed cancer patients based on their tumors histopathology and stage of cancer and assigned them a predetermined path, mostly including surgery, radiotherapy and chemotherapy. However, the results of these combined treatments in solid tumor patients have reached a plateau, said Dr. Hong Now, exciting genomic discoveries have enabled us to identify specific gene mutations in patient tumor tissue that drive cancer cells to grow, and can simultaneously be hijacked by a specific matched targeted agent. Basic, fundamental principles of cancer treatment are changing, now that the genomic makeup of tumor tissue allows us to treat patients with right targeted agents.
Hong continued, MolecularHealth is a unique company with a state of the art facility and highly experienced scientists, along with a robust bioinformatics infrastructure, providing the company with the capability to deliver patients genomic profiling reports to practicing oncologists quickly and accurately.
Lloyd Everson, M.D., CEO of MolecularHealth, Inc., added, Dr. Hong is not only a highly-respected and brilliant oncologist, but an admirable colleague and caring physician. He is a recognized leader in personalized medicine, and we are very pleased to be working with him as we grow MolecularHealths TreatmentMAP offering for cancer patients.
ABOUT MOLECULARHEALTH
MolecularHealth is a leading biomedical company transforming molecular data into actionable clinical information for the most efficient and safest cancer treatment options for each individual cancer patient. By using advanced proprietary tumor analysis and interpretation to match patient-specific genetic and molecular test findings to the current state of the worlds biomedical knowledge about cancer, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individuals cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the worlds leading healthcare and information technology companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, and SAP AG. The company is headquartered in Heidelberg, Germany. U.S. headquarters, including a CLIA-certified NGS lab, are located in The Woodlands, Texas. The company also has offices in Boston, Mass.
Website: www.molecularhealth.com
Blog: www.molecularhealth.com/blog
Twitter: www.twitter.com/molecularhealth
LinkedIn: www.linkedin.com/company/molecularhealth
YouTube: www.youtube.com/user/MolecularHealthInc
Contact:
Jessica Attanasio
Associate Vice President
Gregory FCA
610-228-2112